Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May 4;16(9):1776.
doi: 10.3390/cancers16091776.

The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review

Affiliations
Review

The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review

Saurav Verma et al. Cancers (Basel). .

Abstract

Cholangiocarcinoma (CCA) is a rare cancer of bile ducts. It is associated with a poor prognosis. The incidence of CCA is rising worldwide. Anatomical subgroups have been used to classify patients for treatment and prognosis. There is a growing understanding of clinically important distinctions based on underlying genetic differences that lead to different treatment options and outcomes. Its management is further complicated by a heterogeneous population and relative rarity, which limits the conduct of large trials to guide management. Surgery has been the primary method of therapy for localized disease; however, recurrence and death remain high with or without surgery. Therefore, there have been concerted efforts to investigate new treatment options, such as the use of neoadjuvant treatments to optimize surgical outcomes, targeted therapy, leveraging a new understanding of immunobiology and stereotactic radiation. In this narrative review, we address the evidence to improve suboptimal outcomes in unresectable CCA with radiation, as well as the role of radiation in neoadjuvant and postoperative treatment. We also briefly discuss the recent developments in systemic treatment with targeted therapies and immune checkpoint inhibitors.

Keywords: chemotherapy; cholangiocarcinoma; gallbladder; radiotherapy; surgery; systemic therapy; targeted treatment.

PubMed Disclaimer

Conflict of interest statement

DB has accepted honoraria and/or speaking fees from Astra Zeneca, Amgen, Bristol-Myers Squibb, Takeda, Bayer, Guardant, Roche, Janssen, and Merck. ML has accepted honoraria and/or consulting fees from Tersera, Ferring, Eisai, Tolmar, Abbvie, Bayer, and Knight Therapeutics. The rest of the authors have no conflicts of interest.

Figures

Figure 1
Figure 1
Anatomic subtypes of CCA with associated genetic aberrations (this schematic was created using Servier Medical Art templates, which are licensed under a Creative Commons Attribution 4.0 Unported License; https://smart.servier.com, accessed on 2 February 2024).

Similar articles

References

    1. Doherty B., Nambudiri V.E., Palmer W.C. Update on the Diagnosis and Treatment of Cholangiocarcinoma. Curr. Gastroenterol. Rep. 2017;19:2. doi: 10.1007/s11894-017-0542-4. - DOI - PubMed
    1. Rizvi S., Khan S.A., Hallemeier C.L., Kelley R.K., Gores G.J. Cholangiocarcinoma—Evolving Concepts and Therapeutic Strategies. Nat. Rev. Clin. Oncol. 2018;15:95–111. doi: 10.1038/nrclinonc.2017.157. - DOI - PMC - PubMed
    1. Ramírez-Merino N. Chemotherapy for Cholangiocarcinoma: An Update. World J. Gastrointest. Oncol. 2013;5:171. doi: 10.4251/wjgo.v5.i7.171. - DOI - PMC - PubMed
    1. Chun Y.S., Javle M. Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma. Cancer Control. 2017;24:1073274817729241. doi: 10.1177/1073274817729241. - DOI - PMC - PubMed
    1. Chen Y.-X., Zeng Z.-C., Tang Z.-Y., Fan J., Zhou J., Jiang W., Zeng M.-S., Tan Y.-S. Determining the Role of External Beam Radiotherapy in Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Analysis of 84 Patients. BMC Cancer. 2010;10:492. doi: 10.1186/1471-2407-10-492. - DOI - PMC - PubMed

Grants and funding

This research received no external funding.

LinkOut - more resources